Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.
| 0.4703 | |
| 0.485 | |
| - | |
| 0.4899 | |
| 0.453 | |
| 0.41-3.8978 | |
| 3 746 K | |
| 7 954 K | |
| 35 405 K | |
| -0.42 | |
| 0.479 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Key Takeaways; Cannabis Sector Ayr Wellness reported solid first quarter results. Cresco Labs reported stagnant sales but an optimistic outlook for 2024. Tilray announced a $250 million equity offeri...
NEW YORK, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has initiated coverage of Enveric Bioscience...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
